For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Open-label SSRI | citalopram or escitalopram open-label SSRI : Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion. | None | None | 0 | 47 | 5 | 47 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| weight gain | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| lack of appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| increase in tremors | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| hypomania | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |